Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis

Published on May 4, 2019in Inflammatory Bowel Diseases4.00
· DOI :10.1093/ibd/izy323
Brian G. Feagan94
Estimated H-index: 94
(UWO: University of Western Ontario),
Stefan Schreiber S145
Estimated H-index: 145
(CAU: University of Kiel)
+ 10 AuthorsSharon O’Byrne1
Estimated H-index: 1
(Takeda Pharmaceutical Company)
  • References (26)
  • Citations (1)
#1Jean-Frederic Colombel (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 126
#2Mary E. Keir (Genentech)H-Index: 10
Last.Timothy T. Lu (Genentech)H-Index: 4
view all 7 authors...
#1Siew C. Ng (CUHK: The Chinese University of Hong Kong)H-Index: 44
#2William Palo (Takeda Pharmaceutical Company)H-Index: 3
Last.Fatima Bhayat (Takeda Pharmaceutical Company)H-Index: 3
view all 5 authors...
View next paperLong-term clinical experience with Vedolizumab in patients with mild to moderate Ulcerative Colitis: P-37.